- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Penumbra Inc(PEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PEN
11/13/2026: PEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Penumbra Inc is a specialized medical device company recognized for its role in developing minimally invasive thrombectomy technology for neurovascular and peripheral vascular conditions. The company's growth is fueled by a commitment to physician-led innovation and a robust, vertically integrated business model. Its primary investment story centers on the continued global adoption of its proprietary computer-assisted vacuum technology. However, Penumbra faces significant risks from well-capitalized competitors, pricing pressure from healthcare systems, and the need for ongoing positive clinical results. The stock may suit growth-oriented investors who can tolerate volatility, while those seeking dividends or low-risk stability will likely find the company's investment profile a poor fit.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Penumbra consistently prioritizes high-growth medical technology sectors and reinvests heavily in innovation. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts strongly to new clinical data or commercial adoption signals for its thrombectomy products. |
| Value investor | Weak fit | The company typically trades at high valuation multiples consistent with high-growth medical device stocks. |
| Dividend investor | Weak fit | Penumbra does not pay dividends and focuses all capital on business expansion. |
| Low-risk investor | Weak fit | The stock experiences significant volatility associated with its growth valuation and healthcare sector risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | High growth expectations can lead to sharp price swings based on quarterly earnings or regulatory updates. |
| Valuation risk | Medium / high | The stock's premium valuation leaves little margin for error regarding revenue growth performance. |
| Competition risk (Medical Technology) | High | Large incumbents like Medtronic and Stryker have deep pockets to challenge Penumbra's market position. |
| Business quality | Strong | The company possesses a strong reputation for proprietary, high-quality medical device engineering. |
| Dividend income | Low / none | Investors should not rely on Penumbra for steady income as all cash is reinvested. |
| Execution risk | Medium | Successful commercialization depends on consistent physician adoption and ongoing hospital training. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.65B USD | Price to earnings Ratio 80.83 | 1Y Target Price 362.54 |
Price to earnings Ratio 80.83 | 1Y Target Price 362.54 | ||
Volume (30-day avg) 375.3K shares | Beta 0.69 | 52 Weeks Range 276.01 - 362.41 | Updated Date 11/14/2026 |
52 Weeks Range 276.01 - 362.41 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.97 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Very Smooth
The stock has followed a highly orderly price path with minimal short-term disruption.
Analysis of Past Performance
Type Stock | Historic Profit -4.6% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neurovascular Products | Catheters, coils, and access devices for stroke and brain-related vascular procedures. | Revenue is earned by selling advanced tools doctors use to treat life-threatening strokes. |
| Peripheral Vascular Products | Lightning aspiration systems for removing clots in arms, legs, and lungs. | This is a key area of expansion, targeting common issues like deep vein thrombosis. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 1.21 | Actual 1.07 |
Profitability
Profit Margin 10.06% | Operating Margin (TTM) 12.13% |
Management Effectiveness
Return on Assets (TTM) 6.28% | Return on Equity (TTM) 10.67% |
Valuation
Trailing PE 80.83 | Forward PE 55.87 | Enterprise Value 12.18B | Price to Sales(TTM) 8.11 |
Enterprise Value 12.18B | Price to Sales(TTM) 8.11 | ||
Enterprise Value to Revenue 7.81 | Enterprise Value to EBITDA 53.13 | Shares Outstanding 39.41M | Shares Floating 38.30M |
Shares Outstanding 39.41M | Shares Floating 38.30M | ||
Percent Insiders 6.63 | Percent Institutions 87.1 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

